Market Exclusive

Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Canaccord Genuity with a $65.00 price target

Analyst Ratings For Aerie Pharmaceuticals Inc (NASDAQ:AERI)

Today, Canaccord Genuity reiterated its Buy rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI) with a price target of $65.00.

There are 9 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Hold Ratings on the stock.

The current consensus rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI) is Buy with a consensus target price of $79.10 per share, a potential 67.98% upside.

Some recent analyst ratings include

Recent Trading Activity for Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Shares of Aerie Pharmaceuticals Inc closed the previous trading session at 47,09 +0,11 0,23 % with 45.47 shares trading hands.

Exit mobile version